Search Results
Results found for "David M. Thal"
- Dr. GPCR Spotlights Revvity’s pHSense™ Internalization Tools
A GPCR Internalization Tool Designed for Real Research Needs Built on more than two decade A GPCR Internalization
- Orthosteric Binding Experiments: How to Avoid the Most Common Data Pitfalls
Clues that point to true multiple-site binding rather than two-stage GPCR biology: Disrupting G protein If the tracer binds faster than the displacer, early time points exaggerate tracer occupancy and underestimate
- Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies
and anxiety, has shown, in the last decade, increasing evidence of its antitumoral properties in more than
- Structures of β 1-adrenergic receptor in complex with Gs and ligands of different efficacies
intermediate state complex comprising β1-AR and nucleotide-free Gs is more stable when binding a full agonist than
- Targeted Therapies to Reduce Side Effects in Modern Drug Development
In fact, it is often costly, frustrating, and tortuous—and more often than not it ends in failure.
- Inversago Pharma appoints Glenn S. Vraniak as Chief Financial Officer
Vraniak’s career spans more than 20 years of financial and commercial experience in the life sciences
- Discovery of 3(2-aminoethyl)-thiazolidine-2,4-diones as a novel chemotype of sigma-1 receptor ligand
Six compounds showed more than 50% displacement of the radioligand at 10 µM concentration with compound
- Maria’s Travel Blogs: ACSMEDI-EFMC Medicinal Chemistry Frontiers 2025
This Chemistry Tools session was more industry focused than those before, and Maria shared the floor
- GPCR Therapeutics welcomes Dr. Ed Brennan as their new Vice President, Head of Clinical Development
He has led teams that have filed more than 10 Investigational New Drug Applications (IND), as well as
- Bell-Evans model and steered molecular dynamics in uncovering the dissociation kinetics of ligands..
However, our predictions were many folds shorter than those determined experimentally.
- C5aR2 receptor: The genomic twin of the flamboyant C5aR1
C5aR2 is a nonclassical GPCR that tailors immune cell activity potentially through β-arrestins rather than
- Delineation of GPR15 receptor-mediated Gα protein signaling profile in recombinant mammalian cell
The results show that the GPR15 receptor preferentially couples to Gi/o rather than other pathways in
- Comparative studies of AlphaFold, RoseTTAFold and Modeller: a case study involving the use of...
program's top-scored structure, Modeller had the smallest average modeling RMSD of 2.17 Å, which is better than
- Design and validation of recombinant protein standards for quantitative Western blot analysis of...
density obtained by quantitative Western blot were of the same order of magnitude but slightly higher than
- AlphaFold’s Breakthrough in GPCR Research: Revolutionizing Discovery, Yet Awaiting Experimental Proof
AlphaFold2 outperformed homology models, achieving a 60% hit rate for compounds targeting TAAR1, more than
- GPCR Happy Hour – Boston, Sept 2025
GPCR Happy Hour is more than a social event.
- GASP1 enhances malignant phenotypes of breast cancer cells and decreases their response to...
was highly expressed in breast cancers, and patients harboring altered GASP1 showed a worse prognosis than
- Target Residence Time: The Hidden Driver of In Vivo Efficacy
Time” Now Only in Terry’s Corner Why Terry’s Corner In a world where drug discovery is evolving faster than
- How Fast Does a Drug Work?
Why Faster, Smarter Decisions Require More Than Kd In drug discovery today, the clock is always ticking
- Role of G Protein-Coupled Receptors in Hepatic Stellate Cells and Approaches to Anti-Fibrotic ...
It is predicted that more than 50 GPCRs are expressed in the liver.
- Allosteric Binding Demystified: Smarter GPCR Drug Discovery
With Premium, you move faster, smarter, and more confidently than peers relying on scattered signals.
- Misread the Curve, Misjudge the Drug: Rethinking Antagonism in GPCR Pharmacology
Beyond the Curve: Questions This Lesson Helps You Answer This lesson pushes you to go deeper than surface-level
- GPCR Allosteric Modulation: Why Allostery is the Engine of Drug Discovery
Cryptic Sites, Longer Onset: Why Some Drugs Work Differently in Cells Than in Assays One of the most
- Why Intracellular Drugs May Hold the Key to GPCR Therapeutics
Intracellular Drugs” Now Only in Terry’s Corner Why Terry’s Corner In a world where GPCR science moves faster than
- Platelets in the NETworks interweaving inflammation and thrombosis
In light of the current COVID-19 pandemic, the topic of immunothrombosis has become more relevant than
- Recurrent high-impact mutations at cognate structural positions in class A G protein-coupled ...
Because there are many more GPCRs than effectors, mutations in different receptors could perturb signaling
- Do You Believe AI Could Accelerate Drug Discovery?
Of 161 molecules tested, 42 substituted more than 50% of [³H]-LSD at 10 μM, achieving a 26% hit rate.
- Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST2 and SST5...
internalize both receptors whereas pasireotide promoted robust receptor internalization at shorter times than
- Is Your GPCR Drug Discovery Program Built for Breakthroughs or Breakdowns?
The GPCR Precision Blueprint is more than a concept.
- Predicting GPCR Function: Inside the Carlsson Lab’s Modeling Toolbox
method can’t resolve subtle potency differences, the team prefers to acknowledge that limitation rather than













